Is Nidan Laborator. overvalued or undervalued?

As of 10 November 2025, the valuation grade for Nidan Laborator. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 14.25, an EV to EBITDA of 7.38, and a Price to Book Value of 0.41, all of which suggest that the stock is trading at a discount compared to its intrinsic value.
In comparison with its peers, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 88.71, and also offers a more favorable EV to EBITDA ratio compared to Apollo Hospitals at 28.24. Despite recent underperformance relative to the Sensex, with a year-to-date return of -29.64% against the Sensex's 8.16%, the attractive valuation metrics suggest that Nidan Laborator. may present a compelling investment opportunity moving forward.